Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dynavax Technologies
(NASDAQ:DVAX)
Intraday
$11.01
-0.16
[-1.43%]
After-Hours
$11.01
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$11.01
-0.16
[-1.43%]
At close: Apr 26
$11.01
0
[0.00%]
After Hours: 7:40PM EDT
Get Report
Watch
Q1 2024 Earnings in 10 days from now on Wed May 8th, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Dynavax Technologies Stock (NASDAQ:DVAX)
Dynavax Technologies Stock (NASDAQ: DVAX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, February 22, 2024
Dynavax Technologies Sees FY24 Net Product Revenue $265M-$280M Vs $290.628M Est.
Benzinga Newsdesk
-
Feb 22, 2024, 4:37PM
Dynavax Technologies: Q4 Earnings Insights
Benzinga Insights
-
Feb 22, 2024, 4:05PM
Dynavax Technologies Q4 Sales $55.60M Beat $52.73M Estimate
Benzinga Newsdesk
-
Feb 22, 2024, 4:02PM
Earnings Scheduled For February 22, 2024
Benzinga Insights
-
Feb 22, 2024, 5:27AM
Thursday, February 01, 2024
Goldman Sachs Initiates Coverage On Dynavax Technologies with Neutral Rating, Announces Price Target of $20
Benzinga Newsdesk
-
Feb 1, 2024, 7:00AM
Monday, January 08, 2024
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Jan 8, 2024, 1:36PM
Dynavax Technologies shares are trading lower. The company issued preliminary Q4 and FY23 guidance.
Benzinga Newsdesk
-
Jan 8, 2024, 1:08PM
Dynavax Sees Prelim. 2023 HEPLISAV-B Vaccine Net Product Revenue ~$213M, Up 69% YoY; ~$51M For Q4, Up 46% YoY
Benzinga Newsdesk
-
Jan 8, 2024, 9:06AM
Friday, November 03, 2023
JMP Securities Maintains Market Outperform on Dynavax Technologies, Raises Price Target to $27
Benzinga Newsdesk
-
Nov 3, 2023, 3:43PM
HC Wainwright & Co. Maintains Buy on Dynavax Technologies, Raises Price Target to $28
Benzinga Newsdesk
-
Nov 3, 2023, 6:58AM
Thursday, November 02, 2023
Dynavax Technologies Q3 EPS $0.10, Sales $69.51M Beat $60.30M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 5:33PM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Wednesday, November 01, 2023
Earnings Preview For Dynavax Technologies
Benzinga Insights
-
Nov 1, 2023, 2:01PM
Thursday, September 07, 2023
Cramer Suggests Buying Fast Food Chain Owner Of Popeye's, Burger King: Here's Why
Lisa Levin
-
Sep 7, 2023, 8:34AM
Wednesday, August 09, 2023
Chief Accounting Officer at Dynavax Technologies Exercises Options Worth $117K
Benzinga Insights
-
Aug 9, 2023, 11:02AM
Friday, August 04, 2023
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
Lisa Levin
-
Aug 4, 2023, 10:32AM
HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $27 Price Target
Benzinga Newsdesk
-
Aug 4, 2023, 8:22AM
JMP Securities Maintains Outperform on Dynavax Technologies, Raises Price Target to $25
Benzinga Newsdesk
-
Aug 4, 2023, 7:33AM
Thursday, August 03, 2023
Dynavax Technologies Q2 EPS $0.03 Beats $(0.09) Estimate, Sales $60.25M Beat $48.38M Estimate
Benzinga Newsdesk
-
Aug 3, 2023, 5:10PM
Earnings Scheduled For August 3, 2023
Benzinga Insights
-
Aug 3, 2023, 6:59AM
Wednesday, August 02, 2023
Preview: Dynavax Technologies's Earnings
Benzinga Insights
-
Aug 2, 2023, 3:01PM
Monday, July 31, 2023
Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights
-
Jul 31, 2023, 10:44AM
Monday, July 24, 2023
5 Value Stocks In The Healthcare Sector
Benzinga Insights
-
Jul 24, 2023, 10:44AM
Monday, July 17, 2023
A Look Into Healthcare Sector Value Stocks
Benzinga Insights
-
Jul 17, 2023, 10:44AM
Friday, June 30, 2023
Dynavax Wins $56.2M Contract From Department Of Health And Human Services For '2023 Adult Vaccines'
Benzinga Newsdesk
-
Jun 30, 2023, 1:58PM
Monday, May 29, 2023
5 Value Stocks In The Healthcare Sector
Benzinga Insights
-
May 29, 2023, 10:43AM
Wednesday, May 03, 2023
The Latest Analyst Ratings for Dynavax Technologies
Benzinga Insights
-
May 3, 2023, 2:01PM
JMP Securities Maintains Outperform on Dynavax Technologies, Lowers Price Target to $24
Benzinga Newsdesk
-
May 3, 2023, 6:40AM
HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $27 Price Target
Benzinga Newsdesk
-
May 3, 2023, 6:07AM
Tuesday, May 02, 2023
Dynavax Technologies Q1 EPS $(0.19) Misses $(0.13) Estimate, Sales $46.92M Beat $38.59M Estimate
Happy Mohamed
-
May 2, 2023, 4:40PM
Monday, March 06, 2023
5 Value Stocks In The Healthcare Sector
Benzinga Insights
-
Mar 6, 2023, 9:43AM
Wednesday, March 01, 2023
Dynavax Technologies's Return On Capital Employed Insights
Benzinga Insights
-
Mar 1, 2023, 9:49AM
Friday, February 24, 2023
JMP Securities Maintains Market Outperform Rating for Dynavax Technologies: Here's What You Need To Know
Benzinga Insights
-
Feb 24, 2023, 12:00PM
JMP Securities Maintains Market Outperform on Dynavax Technologies, Raises Price Target to $25
Benzinga Newsdesk
-
Feb 24, 2023, 6:58AM
HC Wainwright & Co. Maintains Buy on Dynavax Technologies, Lowers Price Target to $27
Benzinga Newsdesk
-
Feb 24, 2023, 6:15AM
Thursday, February 23, 2023
Dynavax Sees FY23 HEPLISAV-B Net Product Revenue $165M-$185M
Bill Haddad
-
Feb 23, 2023, 4:11PM
Dynavax Technologies Q4 EPS $0.45 Beats $0.43 Estimate, Sales $184.50M Beat $179.60M Estimate
Bill Haddad
-
Feb 23, 2023, 4:10PM
Earnings Scheduled For February 23, 2023
Benzinga Insights
-
Feb 23, 2023, 5:18AM
Tuesday, January 31, 2023
Dynavax Announces Uplisting To Nasdaq Global Select Market
Michael Horton
-
Jan 31, 2023, 4:36PM
Friday, January 20, 2023
Jim Cramer On This Stock Up 2% Over 6 Months: 'You've Got A Real Winner There'
Priya Nigam
-
Jan 20, 2023, 9:01AM
Monday, January 09, 2023
Dynavax Reports Prelim. FY22 HEPLISAV-B Vaccine Net Product Revenue Of ~$126M, Up 104% YoY
Benzinga Newsdesk
-
Jan 9, 2023, 8:31AM
Wednesday, November 30, 2022
Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission
Vandana Singh
-
Nov 30, 2022, 9:10AM
Friday, November 04, 2022
Goldman Sachs Maintains Buy on Dynavax Technologies, Lowers Price Target to $21
Benzinga Newsdesk
-
Nov 4, 2022, 10:28AM
Thursday, November 03, 2022
Dynavax Technologies Q3 EPS $0.43 Beats $0.33 Estimate, Sales $167.74M Beat $159.41M Estimate
Benzinga Newsdesk
-
Nov 3, 2022, 4:58PM
Earnings Scheduled For November 3, 2022
Benzinga Insights
-
Nov 3, 2022, 5:42AM
Wednesday, November 02, 2022
Earnings Preview For Dynavax Technologies
Benzinga Insights
-
Nov 2, 2022, 12:14PM
Tuesday, September 27, 2022
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2022
Benzinga Insights
-
Sep 27, 2022, 10:05AM
Dynavax Technologies are trading higher after JMP Securities initiated coverage on the stock with a Market Outperform rating and a $22 price target.
Bill Haddad
-
Sep 27, 2022, 9:41AM
JMP Securities Initiates Coverage On Dynavax Technologies with Market Outperform Rating, Announces Price Target of $22
Benzinga Newsdesk
-
Sep 27, 2022, 6:17AM
Monday, September 26, 2022
Short Interest Sector Focus: Healthcare Sector
Christopher Sappo
-
Sep 26, 2022, 10:27AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch